PUBLISHER: Grand View Research | PRODUCT CODE: 1842015
PUBLISHER: Grand View Research | PRODUCT CODE: 1842015
The global transcranial magnetic stimulation system market size was estimated at USD 256.53 million in 2024 and is projected to reach USD 594.49 million by 2033, growing at a CAGR of 9.89% from 2025 to 2033. The global market for transcranial magnetic stimulation system is experiencing significant growth, driven by increasing awareness of neurological disorders, the rising prevalence of neurological and mental health conditions, and a growing number of clinical trials focused on developing innovative TMS systems.
Moreover, the expanding adoption of TMS systems in hospitals and healthcare facilities and a heightened focus on market penetration in both emerging and developed regions are further propelling market expansion. The rising prevalence of neurological disorders, including epilepsy, Parkinson's disease, Alzheimer's disease, obsessive-compulsive disorder (OCD), and depression, is a significant driver for the TMS system industry. According to the WHO data published in February 2024, around 50 million people globally are living with epilepsy. In addition, data from the Alzheimer's Association report published in April 2024 estimates that 6.90 million Americans aged 65 and older are affected by Alzheimer's dementia.
In addition, the WHO reported in August 2025 that approximately 5.7% of the global adult population suffers from depressive disorders. In addition, the study published by the National Library of Medicine in February 2024 reports that OCD is a prevalent disorder that affects around 1% to 3% of the global population. This considerable burden of neurological conditions is expected to fuel the demand for TMS systems, which use magnetic fields to modulate brain activity non-invasively. TMS has proven effective in treating depression and shows promise in managing other neurological disorders.
Furthermore, the growing burden of neurological disorders remains considerable across both developing and developed nations, driving the demand for advanced treatment technologies. For instance, according to the National Institute of Mental Health, an estimated 21.0 million adults in the U.S. experienced at least one major depressive episode in 2021, accounting for 8.3% of the adults. This prevalence highlights the growing need for effective, non-invasive treatment options such as transcranial magnetic stimulation systems.
Companies are endlessly upgrading their existing products by incorporating advanced features and improving user experience to meet the growing needs of researchers and medical professionals. For instance, in July 2025, the updated Magstim Rapid Transcranial Magnetic Stimulation Research System received FDA approval. This enhanced system offers a sleek 15" touchscreen and user-friendly software, thus providing an intuitive interface. Its Windows-based platform allows greater compatibility and all-in-one integration with external devices.
Global Transcranial Magnetic Stimulation System Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global transcranial magnetic stimulation system market report based on type, application, age group, and region: